New hope for myelofibrosis patients with dangerous low platelet counts

NCT ID NCT03165734

Disease control Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and itching. About 400 participants will be randomly assigned to receive either pacritinib or another therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Pacritinib
What this could lead to: If successful, pacritinib could offer a new treatment option for myelofibrosis patients with very low platelet counts, potentially reducing spleen size and improving symptoms.
What could go wrong: This is an advanced phase 3 trial, but the condition is serious and the patient population is difficult to treat. The drug may not prove superior to existing options, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

407 people

The number who actually took part.

Started

Jun 2017

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Diagnosis and Inclusion Criteria 1. Primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF (as defined by Tefferi and Vardiman 2008) 2. Platelet count of \<50,000/μL at Screening (Day -35 to Day -3) 3. Dynamic International Prognostic Scoring System Intermediate-1, Intermediate-2, or High-Risk (Passamonti et al 2010) 4. Palpable splenomegaly ≥5 cm below the lower costal margin in the midclavicular line as assessed by physical examination 5. TSS of ≥10 on the MPN-SAF TSS 2.0 or a single symptom score of ≥5 or two symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats. The TSS criteria need only to be met on a single day. 6. Age ≥18 years 7. Eastern Cooperative Oncology Group performance status 0 to 2 8. Peripheral blast count of \<10% throughout the Screening period prior to randomization 9. Absolute neutrophil count of ≥500/µL 10. Left ventricular cardiac ejection fraction of ≥50% by echocardiogram or multigated acquisition scan 11. Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase \[AST\]/serum glutamic-oxaloacetic transaminase \[SGOT\] and alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\]) ≤3 × the upper limit of normal (ULN) (AST/ALT ≤5 × ULN if transaminase elevation is related to MF), total bilirubin ≤4 x ULN (in cases where total bilirubin is elevated, direct bilirubin ≤4 × ULN, is required) and creatinine ≤2.5 mg/dL 12. Adequate coagulation defined by prothrombin time/international normalized ratio and partial thromboplastin time ≤1.5 × ULN 13. If fertile, willing to use highly effective birth control methods during the study (see Section 7.1.2.6 for acceptable birth control methods) 14. Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the study 15. Able to understand and willing to complete symptom assessments using a patient-reported outcome instrument 16. Provision of signed informed consent Exclusion Criteria 1. Life expectancy \<6 months 2. Completed allogeneic stem cell transplant or are eligible for and willing to complete other approved available therapy including allogeneic stem cell transplant 3. History of splenectomy or planning to undergo splenectomy 4. Splenic irradiation within the last 6 months 5. Previously treated with pacritinib 6. Treatment with any MF-directed therapy within 14 days prior to treatment Day 1 7. Prior treatment with more than one JAK2 inhibitor 8. Prior treatment with with ruxolitinib, if BOTH of the following conditions are met: i. exposure to higher-dose ruxolitinib (\>10 mg daily) within 120 days prior to treatment Day 1 AND ii. total duration of treatment with higher-dose ruxolitinib (\>10 mg daily) was \>90 days, from first to last exposure (i.e., this 90-day period starts on the date of first administration of ruxolitinib at a total daily dose of \>10 mg and continues for 90 calendar days, regardless of whether higher-dose ruxolitinib is administered continuously or intermittently). 9. Prior treatment with any JAK2 inhibitor other than ruxolitinib, irrespective of dose, with a duration of \>90 days. The 90-day period starts on the date of first administration of JAK2 inhibitor therapy and continues for 90 calendar days, regardless of whether therapy is administered continuously or intermittently. 10. Treatment with an experimental therapy, including MF-directed experimental therapies within 28 days prior to treatment Day 1 11. Systemic treatment with a strong cytochrome P450 3A4 (CYP 3A4) inhibitor or a strong CYP 3A4 inducer within 14 days prior to treatment Day 1. Shorter washout periods may be permitted with approval of the Medical Monitor, provided that the washout period is at least five half-lives of the drug prior to treatment Day 1 12. Significant recent bleeding history defined as National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2 within 3 months prior to treatment Day 1, unless precipitated by an inciting event (eg, surgery, trauma, or injury) 13. Systemic treatment with medications that increase the risk of bleeding, including anticoagulants, antiplatelet agents (except for aspirin dosages of ≤100 mg per day),and daily use of cyclooxygenase-1 (COX-1) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to treatment Day 1. Treatment with systemic anti-vascular endothelial growth factor (anti-VEGF) agents within 28 days prior to treatment Day 1. 14. Systemic treatment with medications that can prolong the QT interval within 14 days prior to treatment Day 1. Shorter washout periods may be permitted with approval of the Medical Monitor, provided that the washout period is at least five half-lives of the drug prior to treatment Day 1 15. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within 6 months prior to treatment Day 1. Patients with asymptomatic grade 2 non-dysrhythmia cardiovascular conditions may be considered for inclusion, with the approval of the Medical Monitor, if stable and unlikely to affect patient safety. 16. Any history of CTCAE grade ≥2 cardiac dysrhythmias within 6 months prior to treatment Day 1. Patients with non-corrected QT interval CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the Medical Monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety. 17. QT corrected by the Fridericia method (QTcF) prolongation \>450 ms or other factors that increase the risk for QT interval prolongation (eg, hypokalemia \[defined as serum potassium \<3.0 mEq/L that is persistent and refractory to correction\], or history of long QT interval syndrome). 18. New York Heart Association Class II, III, or IV congestive heart failure 19. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication 20. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation 21. Other malignancy within 3 years prior to treatment Day 1. The following patients may be eligible despite having had a malignancy within the prior 3 years: patients with curatively treated squamous or basal cell carcinoma of the skin; patients with curatively treated non-invasive cancers; patients with organ-confined prostate cancer with prostate specific antigen (PSA) \<20 ng/mL and National Comprehensive Cancer Network risk of Very Low, Low, or Favorable Intermediate; and patients with curatively treated non-metastatic prostate cancer with negative PSA. 22. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection, psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements 23. Known seropositivity for human immunodeficiency (HIV) virus. For patients in Czech Republic, France and Italy only: testing for HIV is required during Screening. 24. Known active hepatitis A, B, or C virus infection. For patients in Czech Republic, France and Italy only: testing for hepatitis B and C is required during Screening. 25. Women who are pregnant or lactating 26. Concurrent enrollment in another interventional trial 27. Severe thrombocytopenia due to vitamin B12 deficiency, folate deficiency, or viral infection in the opinion of the investigator 28. Known hypersensitivity to pacritinib or any of the following inactive ingredients: microcrystalline cellulose, polyethylene glycol, and magnesium stearate; any contraindication to the "physician's choice" medicinal product selected by the investigator to be used as the comparator or to loperamide or equivalent antidiarrheal medication 29. Persons deprived of their liberty by a judicial or administrative decision 30. Persons subject to legal protection measures or unable to express their consent 31. Temporarily incapacitated persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-essential thrombocythemia myelofibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia blood platelet disease bone marrow disorder hematologic disorder hemorrhagic disease primary myelofibrosis Splenomegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-essential thrombocythemia myelofibrosis Post-polycythemia vera myelofibrosis Primary myelofibrosis

Contacts and locations

Locations

ASST Monza - Ospedale San Gerardo

Monza, Italy
ASST Sette Laghi Hospital

Varese, Italy
ASST Spedali Civili Brescia, Hematology Unit

Brescia, Italy
Aktobe Medical Center, Department of Hematology

Aktobe, Kazakhstan
Alfred Hospital, Malignant Hematology and Stem Cell Transplantation Service

Melbourne, Victoria, Australia
All India Institute of Medical Sciences

Dehradun, Uttarakhand, India
American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817, United States
Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Department of Hematology and Bone Marrow Transplantation

Katowice, Poland
Azienda Ospedaliero-Universitaria Careggi

Florence, Italy
Barts Health NHS Trust - The Royal London Hospital

London, United Kingdom, E1 2ES, United Kingdom
Bashkiria State Medical University, Department of Internal Medicine

Ufa, Russia
Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom, G12 0ZD, United Kingdom
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque

Pessac, 33604, France
CHU Hôpital Amiens Sud

Amiens, France, 80054, France
CHU de Nimes - Hopital Universitaire Caremeau

Nîmes, France, 30900, France
Cancer Institute "Giovanni Paolo II", IRCCS

Bari, Italy
Cancer and Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49546, United States
Center for Hematology

Astana, Kazakhstan
Center for Hematology

Ust-Kamenogorsk, Kazakhstan
Centre Hospitalier Lyon-Sud

Pierre-Bénite, France
Cetus Oncology Inc.

Belo Horizonte, Minas Gerais, Brazil
Cherkasy Regional Oncology Dispensary of Cherkasy Oblast Council, Regional Treatment and Diagnostic Hematology Center, Department of Hematology

Cherkasy, Ukraine
City Clinical Hospital #4" under Dnipro City Council

Dnipro, Ukraine
City Clinical Hospital #40

Moscow, Russia
City Clinical Hospital #7, Hematology Department

Almaty, Kazakhstan
City Clinical Hospital n.a. V.V. Veresaev of the Moscow City Health

Moscow, Russia
City Oncological Center

Shymkent, Kazakhstan
City of Health and Science of Turin

Turin, Italy
City of Hope

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44106, United States
Cleveland Clinic Florida

Weston, Florida, 33331, United States
Clinic UZI 4D, LLC

Pyatigorsk, Russia
Clinical Center of Serbia, Clinic of Hematology

Belgrade, Serbia
Clinical Center of Vojvodina, Clinic of Hematology

Novi Sad, Serbia
Clinical Hospital of the Federal University of Parana (HC - UFPR)

Curitiba, Paraná, Brazil
Clinics Hospital, Federal University of Goias - (UFG)

Goiânia, Goiás, Brazil
Coltea Clinical Hospital

Bucharest, Romania
Columbia University Medical Center

New York, New York, 10017, United States
Communal Non-profit enterprise "Regional Center of Oncology", Department of Hematology

Kharkiv, Ukraine
Comprehensive Cancer Centers of Nevada- Twain Office

Las Vegas, Nevada, 89169, United States
Duke University Hospital

Durham, North Carolina, 27710, United States
Eastern Regional Health Authority

St. John's, Newfoundland and Labrador, Canada
Ehime University Hospital

Tōon, Japan
Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine I

Székesfehérvár, Hungary
Fortis Memorial Research Institute(FMRI)

Gurgaon, Haryana, India
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology,

Rzeszów, Poland
Fukushima Medical University Hospital

Fukushima, Japan
Fundeni Clinical Institute

Bucharest, Romania
Gauhati Medical College and Hospital

Guwahati, Assam, India
George Washington University-Medical Faculty Associates

Washington D.C., District of Columbia, 20037, United States
Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Gloucestershire Royal Hospital

Gloucester, United Kingdom
Grodno University Hospital

Grodno, Belarus
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

London, United Kingdom
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Hadassah Medical Center, Department of Hematology,

Jerusalem, Israel
Hematology Center

Karaganda, Kazakhstan
Hospital "Infermi" of Rimini

Rimini, Italy
Hospital Amaral Carvalho

Jaú, São Paulo, Brazil
Hospital Clínic de Barcelona

Barcelona, Spain
Hospital Moinhos de Vento

Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Rafael

Salvador, Estado de Bahia, Brazil
Hospital Universitario Ramón y Cajal

Madrid, Spain
Hospital del Mar

Barcelona, Spain
Humane Clinic / Atena Research Institute

Mossoró, Rio Grande do Norte, Brazil
Hôpital Saint-Louis

Paris, France
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Imperial College Healthcare NHS Trust - Hammersmith Hospital

London, United Kingdom
Independent Public Teaching Hospital No.1 in Lublin, Department of Hematooncology, Bone Marrow Transplantation and Chemotherapy

Lublin, Poland
Institute of Blood Pathology and Transfusion Medicine, Department of Hematology

Lviv, Ukraine
Institute of Hematology and Transfusion Medicine, Teaching Department of Hematology

Warsaw, Poland
Integrare Therapeutics

Fortaleza, Ceará, Brazil
Integrated Oncology Center of Rio Grande do Sul - Mother of God Hospital

Porto Alegre, Rio Grande do Sul, Brazil
JSC K. Eristavi National Center For Experimental and Clinical Surgery

Tbilisi, Georgia
Jan Mikulicz Radecki University Hospital in Wroclaw, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation

Wroclaw, Poland
Jedrzej Sniadecki Specialist Hospital in Nowy Sacz, Department of Hematology

Nowy Sącz, Poland
Jewish General Hospital; Clinical Research Unit

Montreal, Quebec, Canada
Jewish Hospital Albert Einstein

São Paulo, São Paulo, Brazil
Johns Hopkins University

Baltimore, Maryland, 21287, United States
Juntendo University Hospital

Tokyo, Japan
Kyiv City Clinical Hospital #9, Hematology Department #1

Kyiv, Ukraine
Kyiv Regional Oncology Center, Department of Hematology,

Kyiv, Ukraine
Kyungpook National University Hospital

Daegu, South Korea
Kyushu University Hospital

Fukuoka, Japan
LTD M.Zodelava's Hematology Center, Department of Hematology

Tbilisi, Georgia
LTD S.Khechinashvili University Hospital

Tbilisi, Georgia
La Conception Hospital

Marseille, France
Lady Davis Carmel Medical Center, Department of Hematology,

Haifa, Israel
Limited Liability Company "City Doctor"

Kyiv, Ukraine
Maggiore Polyclinic Hospital, Fondazione IRCCS Ca' Granda

Milan, Italy
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LTD

Tbilisi, Georgia
Maryland Oncology Hematology, PA- Columbia

Columbia, Maryland, 21044, United States
Max Super Speciality Hospital Saket (A Unit of Max Healthcare Institute Limited)

Delhi, India
Mayo Clinic Hospital

Phoenix, Arizona, 85054, United States
Mays Cancer Center

San Antonio, Texas, 78229, United States
Meenakshi Mission Hospital And Research Centre (MMHRC)

Madurai, Tamil Nadu, India
Meir Medical Center, Hematology Institute and Blood Bank

Kfar Saba, Israel
Memorial Sloan -Kettering Cancer Center

New York, New York, 10065, United States
Michigan Medicine Hematology Clinic-Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
Mie University Hospital

Tsu, Japan
Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology

Minsk, Belarus
Morales Meseguer University General Hospital, Department of Hematology and Hemotherapy

Murcia, Spain
Multiprofile Hospital for Active Treatment "Sveta Marina"

Varna, Bulgaria
Multiprofile Hospital for Active Treatment - Sofia, part of Military Medical Academy

Sofia, Bulgaria
Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka

Torun, Poland
National Research Oncology, Oncohematology Center

Astana, Kazakhstan
Netaji Subhash Chandra Bose Cancer Research Institute

Kolkata, West Bengal, India
Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz

Lodz, Poland
Nippon Medical School Hospital

Tokyo, Japan
Nirmal Hospital Pvt Ltd

Surat, Gujarat, India
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Nova Scotia Health Authority, Centre for Clinical Research

Halifax, Nova Scotia, Canada
Ochsner Medical Center

New Orleans, Louisiana, 70121, United States
Onco Card Srl

Brasov, Romania
Oregon Health and Science University

Portland, Oregon, 97239-3098, United States
Oxford University Hospitals NHS Trust - Churchill Hospital

Oxford, United Kingdom
Poltava M.V. Sklifosovskyi Regional Clinical Hospital under Poltava Regional Council, Department of Hematology

Poltava, Ukraine
Polyclinic S. Orsola-Malpighi

Bologna, Italy
Polyclinic San Matteo, IRCCS

Pavia, Italy
Postgraduate Institute of Medical Education and Research (PGIMER)

Chandigarh, Chandigarh, India
Pratia Oncology Katowice

Katowice, Poland
Princess Margaret Cancer Centre

Toronto, Ontario, Canada
Prof. Dr. Ion Chiricuta" Institute of Oncology

Cluj-Napoca, Romania
Providence Hematology - Vancouver

Vancouver, British Columbia, Canada
Pusan National University Hospital

Busan, South Korea
Rabin Medical Center, Clinic for Myeloproliferative Disorders

Petah Tikva, Israel
Regional Cancer Care Associates LLC - CCBD Division

Bethesda, Maryland, 20817, United States
Republican Research Center for Radiation Medicine and Human Ecology

Homyel, Belarus
Research Institute of Hematology and Transfusiology

Saint Petersburg, Russia
Rocky Mountain Cancer Centers (US Oncology/McKesson)

Boulder, Colorado, 80303, United States
Royal Hallamshire Hospital, Department of Hematology

Sheffield, South Yorkshire, United Kingdom
Rush University Medical Center

Chicago, Illinois, 60612, United States
S.M. Kirov Military Medical Academy, Department and Clinic for Intermediate-Level Training in Internal Medicine, Hematology Division

Saint Petersburg, Russia
S.P. Botkin City Clinical Hospital

Moscow, Russia
Sahyadri Super Speciality Hospital

Pune, Maharashtra, India
Saint Agnes Hospital

Baltimore, Maryland, 21229, United States
Saint Lucas Hospital of Copacabana

Rio de Janeiro, Rio de Janeiro, Brazil
Samaritano Hospital

São Paulo, São Paulo, Brazil
Samsung Medical Center

Seoul, South Korea
Santa Catarina Health Research and Education Center (CEPEN)

Florianópolis, Santa Catarina, Brazil
Santa Maria della Misericordia University Hospital of Udine

Udine, Italy
Sao Paulo University Clinical Hospital

São Paulo, São Paulo, Brazil
Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), IRCCS

Forlì, Italy
Semmelweis University SE ÁOK I. sz. Belgyógyászati Klinika

Budapest, Hungary
Seoul National University Hospital

Seoul, South Korea
Severance Hospital

Seoul, South Korea, 3722, South Korea
Shri Ram Cancer Centre, Mahatma Gandhi Medical College & Hospital

Jaipur, Rajasthan, India
Somogy Megyei Kaposi Mór Oktató Kórház

Kaposvár, Hungary
Specialized Hospital for Active Treatment of Hematological Diseases

Sofia, Bulgaria
St. John's Medical College Hospital

Bengaluru, India
State University of Campinas (UNICAMP) - Hemocenter

Campinas, São Paulo, Brazil
Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology

Nyíregyháza, Hungary
Tata Medical Center

Kolkata, West Bengal, India
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC

Tbilisi, Georgia
Texas Oncology- San Antonio

San Antonio, Texas, 78240, United States
The Catholic University of Korea, St. Mary's Hospital

Seoul, South Korea
The James Cancer Hospital and Solove Research Institute

Columbus, Ohio, 43210, United States
The Perth Blood Institute

Perth, Western Australia, Australia
The Sarah Cannon Research Institute-Tennessee Oncology

Nashville, Tennessee, 37203, United States
The Tel Aviv Sourasky Medical Center, Department of Internal Medicine

Tel Aviv, Israel
The University of Chicago Medical Center

Chicago, Illinois, 60637, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Tohoku University Hospital

Miyagi, Japan
Tokyo Medical University Hospital

Tokyo, Japan
Tom Baker Cancer Center, Internal Medicine/Hematology

Calgary, Alberta, Canada
UCLA David Geffen School of Medicine

Los Angeles, California, 90095, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Umberto I Polyclinic of Rome

Rome, Italy
United Hospitals Villa Sofia Cervello

Palermo, Italy
University Clinical Center in Gdansk

Gdansk, Poland
University Clinical Center of Sarajevo

Sarajevo, Bosnia and Herzegovina
University Clinical Centre of the Republic of Srpska

Banja Luka, Bosnia and Herzegovina
University Clinical Hospital of Salamanca, Department of Hematology

Salamanca, Spain
University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology

Valencia, Spain
University Hospital "Federico II"

Naples, Italy
University Hospital "Maggiore della Carita" of Novara

Novara, Italy
University Hospital 12 de Octubre, Department of Hematology

Madrid, Spain
University Hospital Brno

Brno, Czechia
University Hospital Center of Poitiers

Poitiers, France
University Hospital Kralovske Vinohrady, Clinic of Internal Hematology

Prague, Czechia
University Hospital Olomouc

Olomouc, Czechia
University Hospital Plzen

Pilsen, Czechia
University Hospital Vall d'Hebron

Barcelona, Spain
University Hospital Virgen del Rocio (HUVR)

Seville, Spain
University Hospital in Krakow

Krakow, Poland
University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski"

Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv

Plovdiv, Bulgaria
University Polyclinic Foundation "Agostino Gemelli"

Rome, Italy
University Teaching Hospital in Bialystok

Bialystok, Poland
University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center

Birmingham, Alabama, 35294, United States
University of Alberta

Edmonton, Alberta, Canada
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
University of Debrecen Clinical Center (Debreceni Egyetem Klinikai Központ)

Debrecen, Hungary
University of Kansas Cancer Center and Medical Pavilion

Westwood, Kansas, 66205, United States
University of Miyazaki Hospital

Miyazaki, Japan
University of Rochester

Rochester, New York, 14642, United States
University of Utah - Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
University of Yamanashi Hospital

Chūō, Japan
V.A. Almazov North-West Federal Medical Research Center, Institute of Oncology and Hematology, Scientific Department of Clinical Oncology

Saint Petersburg, Russia
Volgograd Regional Clinical Oncology Center

Volgograd, Russia
Washington University School of Medicine-Siteman Cancer Center

St Louis, Missouri, 63110, United States
Weill Cornell Medical College

New York, New York, 10021, United States
Westmead Hospital

Sydney, New South Wales, Australia
Yale School of Medicine

New Haven, Connecticut, 06510, United States
Yashoda Hospitals

Hyderabad, Telangana, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.